BDH Industries Ltd has fixed Friday, August 7, 2026, as the record date to determine shareholder eligibility for a dividend of ₹5 per equity share. The dividend, recommended by the Board of Directors for the financial year ended March 31, 2026, is subject to approval at the upcoming Annual General Meeting (AGM). The company reported a 44% increase in net profit to ₹1081.38 lakh for FY26, supported by a 44% rise in total income to ₹9819.84 lakh.

The 36th AGM is scheduled for Friday, August 14, 2026, at 3 p.m. via Video Conferencing (VC) and Other Audio Visual Means (OVAM). The register of members will remain closed from Saturday, August 8, 2026, to Friday, August 14, 2026, both days inclusive. Shareholders listed in the Register of Members as of the close of business hours on the record date will be entitled to receive the dividend and vote at the meeting. The meeting will be conducted in compliance with the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance for FY26

The growth in total income was driven by both domestic and export sales. Domestic income increased to ₹4817.35 lakh, while export income rose to ₹5002.49 lakh during the year. The company transferred ₹162.21 lakh to the General Reserve from the net profit for FY26.

Key AGM and Dividend Details

Remote e-voting facilities will be provided by National Securities Depository Limited (NSDL).

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE278D01018/213a7767-378b-48de-9dfe-f1f6aa13d8c9.pdf

BDH Industries Limited has announced its audited standalone financial results for the fourth quarter and fiscal year ended March 31, 2026. The company reported a net profit of ₹1081.38 lakh for the full year, marking a 16.6% increase over the ₹927.33 lakh recorded in the previous fiscal year. Revenue from operations for FY26 surged to ₹9595.46 lakh from ₹6650.83 lakh in FY25, driven by strong performance across its pharmaceutical and renewable energy segments.

For the quarter ended March 31, 2026, the company posted a net profit of ₹287.91 lakh, compared to ₹248.87 lakh in the corresponding quarter of the previous year. Quarterly revenue from operations increased to ₹2903.23 lakh from ₹1782.16 lakh in the same period last year. The board has recommended a dividend of ₹5 per equity share of face value ₹10 each for the fiscal year 2025-26, pending approval by shareholders at the 36th Annual General Meeting scheduled for August 14, 2026.

Financial Performance Overview

The company's total income for the year rose to ₹9819.84 lakh from ₹6834.71 lakh in the prior year. Profit before tax for FY26 stood at ₹1519.39 lakh, an improvement from ₹1246.71 lakh in FY25. Earnings per share (EPS) for the year increased to ₹18.78 from ₹16.11 in the previous year. The statutory auditors, M/s. CLB & Associates, issued an unmodified opinion on the audited standalone financial results.

Segment-wise Results

Operations are primarily divided into Pharmaceuticals and Renewable Energy segments. The Pharmaceutical segment contributed the majority of the revenue, reporting ₹9509.31 lakh for the year ended March 31, 2026, while the Renewable Energy segment contributed ₹86.15 lakh. The total assets of the company as of March 31, 2026, stood at ₹9908.51 lakh, compared to ₹8693.81 lakh in the previous year.

Corporate Governance Updates

In addition to the financial results, the board appointed Chhajed Kedia & Associates as Internal Auditors and Krishna S. & Associates as Cost Auditors for FY 2026-27. The board also recommended the appointment of Ms. Karthika Nair as Director retiring by rotation, subject to shareholder approval. The 36th Annual General Meeting will be held via Video Conferencing on August 14, 2026.